Conway A-M, Mitchell C, Kilgour E, Brady G, Dive C, Cook N. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’. Br J Cancer. 2019;120:141–53.
Google Scholar
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70–82.
Google Scholar
Le TMD, Duong HTT, Thambi T, Giang Phan VH, Jeong JH, Lee DS. Bioinspired pH- and temperature-responsive injectable adhesive hydrogels with polyplexes promotes skin wound healing. Biomacromolecules. 2018;19:3536–48.
Google Scholar
Harrington K, Freeman DJ, Kelly B, Harper J, Soria J-C. Optimizing oncolytic virotherapy in cancer treatment. Nat Rev Drug Discov. 2019;18:689–706.
Google Scholar
Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658–70.
Google Scholar
Raja J, Ludwig JM, Gettinger SN, Schalper KA, Kim HS. Oncolytic virus immunotherapy: future prospects for oncology. J Immunother Cancer. 2018;6:140.
Google Scholar
Min L. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18:171–6.
Google Scholar
Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016;4:53.
Google Scholar
Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14:642–62.
Google Scholar
Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018;18:498–513.
Google Scholar
Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629–805629.
Google Scholar
Lenaerts L, van Dam W, Persoons L, Naesens L. Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans. PLoS ONE. 2012;7:e31454–e31454.
Google Scholar
Alba R, Bradshaw AC, Mestre-Francés N, Verdier JM, Henaff D, Baker AH. Coagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus). Gene Ther. 2012;19:109–13.
Google Scholar
Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13:421–33.
Google Scholar
Lemos de Matos A, Franco LS, McFadden G. Oncolytic viruses and the immune system: the dynamic duo. Mol Ther Methods Clin Dev. 2020;17:349–58.
Google Scholar
Kim J, Kim P-H, Kim SW, Yun C-O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials. 2012;33:1838–50.
Google Scholar
Thacker EE, Timares L, Matthews QL. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines. 2009;8:761–77.
Google Scholar
Kaygisiz K, Synatschke CV. Materials promoting viral gene delivery. Biomater Sci. 2020;8:6113–56.
Google Scholar
Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther. 2008;16:16–29.
Google Scholar
Hill C, Grundy M, Bau L, Wallington S, Balkaran J, Ramos V, et al. Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Mol Ther – Oncolytics. 2021;21:47–61.
Google Scholar
Capasso C, Hirvinen M, Cerullo V. Beyond gene delivery: strategies to engineer the surfaces of viral vectors. Biomedicines. 2013;1:3–16.
Google Scholar
Wang IJ, Jhuang M-C, Chen Y-H, Yeh L-K, Liu C-Y, Young T-H. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS ONE. 2010;5:e12085–e12085.
Google Scholar
Sun Y, Lv X, Ding P, Wang L, Sun Y, Li S, et al. Exploring the functions of polymers in adenovirus-mediated gene delivery: Evading immune response and redirecting tropism. Acta Biomaterialia. 2019;97:93–104.
Google Scholar
Hoang Thi TT, Pilkington EH, Nguyen DH, Lee JS, Park KD, Truong NP. The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation. Polymers. 2020;12:298.
Google Scholar
Gupta V, Bhavanasi S, Quadir M, Singh K, Ghosh G, Vasamreddy K, et al. Protein PEGylation for cancer therapy: bench to bedside. J Cell Commun Signal. 2019;13:319–30.
Google Scholar
Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv drug Deliv Rev. 2016;99:28–51.
Google Scholar
Gokarn YR, McLean M, Laue TM. Effect of PEGylation on protein hydrodynamics. Mol Pharmaceutics. 2012;9:762–73.
Google Scholar
Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11:66–79.
Google Scholar
Kim J, Li Y, Kim SW, Lee DS, Yun C-O. Therapeutic efficacy of a systemically delivered oncolytic adenovirus – Biodegradable polymer complex. Biomaterials. 2013;34:4622–31.
Google Scholar
O’Riordan CR, Lachapelle A, Delgado C, Parkes C, Wadsworth SE, Smith AE, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Ther. 1999;10:1349–58.
Google Scholar
Croyle MA, Chirmule N, Zhang Y, Wilson JM. “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung. J Virol. 2001;75:4792.
Google Scholar
Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther. 2002;13:1887–900.
Google Scholar
Geest BD, Snoeys J, Linthout SV, Lievens J, Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Human Gene Ther. 2005;16: 1439–51.
Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 2005;12:579–87.
Google Scholar
Nguyen TV, Heller GJ, Barry ME, Crosby CM, Turner MA, Barry MA. Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. Mol Ther – Oncolytics. 2016;3:15021.
Google Scholar
Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20:975–88.
Google Scholar
Gao J-Q, Eto Y, Yoshioka Y, Sekiguchi F, Kurachi S, Morishige T, et al. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J Controlled Release. 2007;122:102–10.
Google Scholar
Wortmann A, Vöhringer S, Engler T, Corjon S, Schirmbeck R, Reimann J, et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther. 2008;16:154–62.
Google Scholar
Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther. 2008;19:1369–82.
Google Scholar
Yao X, Yoshioka Y, Morishige T, Eto Y, Watanabe H, Okada Y, et al. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009;16:1395–404.
Google Scholar
Wonganan P, Croyle MA. PEGylated adenoviruses: from mice to monkeys. Viruses. 2010;2:468–502.
Google Scholar
Beatty MS, Curiel DT. Chapter two–adenovirus strategies for tissue-specific targeting. Adv Cancer Res. 2012;115:39–67.
Google Scholar
Krutzke L, Prill JM, Engler T, Schmidt CQ, Xu Z, Byrnes AP, et al. Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: preventing vector clearance and preserving infectivity. J Controlled Release. 2016;235:379–92.
Google Scholar
Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001;8:341–8.
Google Scholar
Green NK, Herbert CW, Hale SJ, Hale AB, Mautner V, Harkins R, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004;11:1256–63.
Google Scholar
Fisher KD, Green NK, Hale A, Subr V, Ulbrich K, Seymour LW. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. J Drug Target. 2007;15:546–51.
Google Scholar
Ahi YS, Bangari DS, Mittal SK. Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther. 2011;11:307–20.
Google Scholar
Lovett JR, Ratcliffe LPD, Warren NJ, Armes SP, Smallridge MJ, Cracknell RB, et al. A robust cross-linking strategy for block copolymer worms prepared via polymerization-induced self-assembly. Macromolecules. 2016;49:2928–41.
Google Scholar
Pearce AK, O’Reilly RK. Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. Bioconjugate Chem. 2019;30:2300–11.
Google Scholar
Large DE, Soucy JR, Hebert J, Auguste DT. Advances in receptor-mediated, tumor-targeted drug delivery. Adv. Ther. 2019;2:1800091.
Liu Q, Jin C, Wang Y, Fang X, Zhang X, Chen Z, et al. Aptamer-conjugated nanomaterials for specific cancer cell recognition and targeted cancer therapy. NPG Asia Mater. 2014;6:e95–e95.
Google Scholar
Eto Y, Gao J-Q, Sekiguchi F, Kurachi S, Katayama K, Maeda M, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med. 2005;7:604–12.
Google Scholar
Yao X, Yoshioka Y, Morishige T, Eto Y, Narimatsu S, Kawai Y, et al. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol Ther. 2011;19:1619–25.
Google Scholar
Pandol S, Edderkaoui M, Gukovsky I, Lugea A, Gukovskaya A. Desmoplasia of pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2009;7:S44–S47.
Google Scholar
Yin X, Wang M, Wang H, Deng H, He T, Tan Y, et al. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids. 2017;49:1325–35.
Google Scholar
Na Y, Choi J-W, Kasala D, Hong J, Oh E, Li Y, et al. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model. J Controlled Release. 2015;220:766–82.
Google Scholar
Ono YJ, Terai Y, Tanabe A, Hayashi A, Hayashi M, Yamashita Y, et al. Decorin induced by progesterone plays a crucial role in suppressing endometriosis. J Endocrinol. 2014;223:203–16.
Google Scholar
Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929–58.
Google Scholar
Zhang W, Ge Y, Cheng Q, Zhang Q, Fang L, Zheng J. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment. Oncotarget. 2018;9:5480–91.
Google Scholar
Kim P-H, Sohn J-H, Choi J-W, Jung Y, Kim SW, Haam S, et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials. 2011;32:2314–26.
Google Scholar
Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther. 2002;5:463–72.
Google Scholar
Ulbrich K, Holá K, Šubr V, Bakandritsos A, Tuček J, Zbořil R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116:5338–431.
Google Scholar
Morrison J, et al. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Hum Gene Ther. 2009;20:239–51.
Google Scholar
Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev. Biol. 2015;4:215–66.
Google Scholar
Cao M, De Mel N, Jiao Y, Howard J, Parthemore C, Korman S, et al. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis. MAbs. 2019;11:1064–76.
Google Scholar
Green NK, Morrison J, Hale S, Briggs SS, Stevenson M, Subr V, et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J Gene Med. 2008;10:280–9.
Google Scholar
Duong HTT, Yin Y, Thambi T, Nguyen TL, Giang Phan VH, Lee MS, et al. Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy. Biomaterials. 2018;185:13–24.
Google Scholar
Duong HTT, Kim NW, Thambi T, Giang Phan VH, Lee MS, Yin Y, et al. Microneedle arrays coated with charge reversal pH-sensitive copolymers improve antigen presenting cells-homing DNA vaccine delivery and immune responses. J Controlled Release. 2018;269:225–34.
Google Scholar
Han S-O, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000;2:302–17.
Google Scholar
Choi J-W, Lee J-S, Kim SW, Yun C-O. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev. 2012;64:720–9.
Google Scholar
Kim P-H, Kim J, Kim T-I, Nam HY, Yockman JW, Kim M, et al. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration. Biomaterials. 2011;32:9328–42.
Google Scholar
Sun X-X, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sin. 2015;36:1219–27.
Google Scholar
Wang C-HK, Chan LW, Johnson RN, Chu DSH, Shi J, Schellinger JG, et al. The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus. Biomaterials. 2011;32:9536–45.
Google Scholar
Francini N, Cochrane D, Illingworth S, Purdie L, Mantovani G, Fisher K, et al. Polyvalent diazonium polymers provide efficient protection of oncolytic adenovirus enadenotucirev from neutralizing antibodies while maintaining biological activity in vitro and in vivo. Bioconjugate Chem. 2019;30:1244–57.
Google Scholar
Choi J-W, Kim J, Bui QN, Li Y, Yun C-O, Lee DS, et al. Tuning surface charge and pegylation of biocompatible polymers for efficient delivery of nucleic acid or adenoviral vector. Bioconjugate Chem. 2015;26:1818–29.
Google Scholar
Lee C-H, Kasala D, Na Y, Lee MS, Kim SW, Jeong JH, et al. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression. Biomaterials. 2014;35:5505–16.
Google Scholar
Sung YK, Kim SW. Recent advances in the development of gene delivery systems. Biomater Res. 2019;23:8.
Google Scholar
Hall A, Lächelt U, Bartek J, Wagner E, Moghimi SM. Polyplex evolution: understanding biology, optimizing performance. Mol Ther: J Am Soc Gene Ther. 2017;25:1476–90.
Google Scholar
Zhang H, Chen Z, Du M, Li Y, Chen Y. Enhanced gene transfection efficiency by low-dose 25 kDa polyethylenimine by the assistance of 1.8 kDa polyethylenimine. Drug Deliv. 2018;25:1740–5.
Google Scholar
Lee JY, Hong JW, Thambi T, Yoon A-R, Choi J-W, Li Y, et al. Optimizing active tumor targeting biocompatible polymers for efficient systemic delivery of adenovirus. Cells. 2021;10:1896.
Google Scholar
Kafil V, Omidi Y. Cytotoxic impacts of linear and branched polyethylenimine nanostructures in a431 cells. Bioimpacts. 2011;1:23–30.
Google Scholar
Choi J-W, Nam J-P, Nam K, Lee YS, Yun C-O, Kim SW. Oncolytic adenovirus coated with multidegradable bioreducible core-cross-linked polyethylenimine for cancer gene therapy. Biomacromolecules. 2015;16:2132–43.
Google Scholar
Jung S-J, Kasala D, Choi J-W, Lee S-H, Hwang JK, Kim SW, et al. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model. Biomacromolecules. 2015;16:87–96.
Google Scholar
Ou M, Wang X-L, Xu R, Chang C-W, Bull DA, Kim SW. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjugate Chem. 2008;19:626–33.
Google Scholar
Na Y, Nam J-P, Hong J, Oh E, Shin HC, Kim HS, et al. Systemic administration of human mesenchymal stromal cells infected with polymer-coated oncolytic adenovirus induces efficient pancreatic tumor homing and infiltration. J Controlled Release. 2019;305:75–88.
Google Scholar
Duong HTT, Thambi T, Yin Y, Lee JE, Seo YK, Jeong JH, et al. Smart pH-responsive nanocube-controlled delivery of DNA vaccine and chemotherapeutic drugs for chemoimmunotherapy. ACS Appl Mater Interfaces. 2019;11:13058–68.
Google Scholar
Choi J-W, Jung S-J, Kasala D, Hwang JK, Hu J, Bae YH, et al. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis. J Controlled Release. 2015;205:134–43.
Google Scholar
Choi J-W, Dayananda K, Jung S-J, Lee S-H, Kim D, Hu J, et al. Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration. Acta Biomaterialia. 2015;28:86–98.
Google Scholar
Verbeke CS, Mooney DJ. Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells. Adv Healthc Mater. 2015;4:2677–87.
Google Scholar
Park Y, Kang E, Kwon O-J, Hwang T, Park H, Lee JM, et al. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J Controlled Release. 2010;148:75–82.
Google Scholar
Kwon O-J, Kang E, Choi J-W, Kim SW, Yun C-O. Therapeutic targeting of chitosan–PEG–folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. J Controlled Release. 2013;169:257–65.
Google Scholar
Yoon AR, Kasala D, Li Y, Hong J, Lee W, Jung S-J, et al. Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. J Controlled Release. 2016;231:2–16.
Google Scholar
Ireson CR, Alavijeh MS, Palmer AM, Fowler ER, Jones HJ. The role of mouse tumour models in the discovery and development of anticancer drugs. Br J Cancer. 2019;121:101–8.
Google Scholar
Kim J, Nam HY, Kim T-I, Kim P-H, Ryu J, Yun C-O, et al. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials. 2011;32:5158–66.
Google Scholar
